1. Home
  2. OBDC vs NUVL Comparison

OBDC vs NUVL Comparison

Compare OBDC & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blue Owl Capital Corporation

OBDC

Blue Owl Capital Corporation

N/A

Current Price

$12.95

Market Cap

6.3B

Sector

Finance

ML Signal

N/A

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

N/A

Current Price

$101.27

Market Cap

7.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OBDC
NUVL
Founded
2015
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
7.1B
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
OBDC
NUVL
Price
$12.95
$101.27
Analyst Decision
Buy
Strong Buy
Analyst Count
7
14
Target Price
$14.50
$134.29
AVG Volume (30 Days)
6.0M
748.2K
Earning Date
11-05-2025
10-30-2025
Dividend Yield
12.02%
N/A
EPS Growth
N/A
N/A
EPS
1.39
N/A
Revenue
$1,797,946,000.00
N/A
Revenue This Year
$19.12
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.33
N/A
Revenue Growth
11.43
N/A
52 Week Low
$11.65
$55.54
52 Week High
$15.73
$112.88

Technical Indicators

Market Signals
Indicator
OBDC
NUVL
Relative Strength Index (RSI) 49.11 45.44
Support Level $12.92 $103.52
Resistance Level $13.45 $107.99
Average True Range (ATR) 0.20 3.11
MACD -0.03 -1.20
Stochastic Oscillator 0.76 2.13

Price Performance

Historical Comparison
OBDC
NUVL

About OBDC Blue Owl Capital Corporation

Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: